Cargando…

Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α

Spatiotemporal regulation of tumor immunity remains largely unexplored. Here we identify a vascular niche that controls alternative macrophage activation in glioblastoma (GBM). We show that tumor-promoting macrophages are spatially proximate to GBM-associated endothelial cells (ECs), permissive for...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qirui, He, Zhenqiang, Huang, Menggui, Liu, Tianrun, Wang, Yanling, Xu, Haineng, Duan, Hao, Ma, Peihong, Zhang, Lin, Zamvil, Scott S., Hidalgo, Juan, Zhang, Zhenfeng, O’Rourke, Donald M., Dahmane, Nadia, Brem, Steven, Mou, Yonggao, Gong, Yanqing, Fan, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805734/
https://www.ncbi.nlm.nih.gov/pubmed/29422647
http://dx.doi.org/10.1038/s41467-018-03050-0
Descripción
Sumario:Spatiotemporal regulation of tumor immunity remains largely unexplored. Here we identify a vascular niche that controls alternative macrophage activation in glioblastoma (GBM). We show that tumor-promoting macrophages are spatially proximate to GBM-associated endothelial cells (ECs), permissive for angiocrine-induced macrophage polarization. We identify ECs as one of the major sources for interleukin-6 (IL-6) expression in GBM microenvironment. Furthermore, we reveal that colony-stimulating factor-1 and angiocrine IL-6 induce robust arginase-1 expression and macrophage alternative activation, mediated through peroxisome proliferator-activated receptor-γ-dependent transcriptional activation of hypoxia-inducible factor-2α. Finally, utilizing a genetic murine GBM model, we show that EC-specific knockout of IL-6 inhibits macrophage alternative activation and improves survival in the GBM-bearing mice. These findings illustrate a vascular niche-dependent mechanism for alternative macrophage activation and cancer progression, and suggest that targeting endothelial IL-6 may offer a selective and efficient therapeutic strategy for GBM, and possibly other solid malignant tumors.